S&P 500   3,003.80 (-0.10%)
DOW   26,865.18 (+0.14%)
QQQ   192.41 (-0.51%)
AAPL   240.85 (+0.14%)
MSFT   136.93 (-1.08%)
GOOGL   1,241.08 (-0.26%)
AMZN   1,766.27 (-1.09%)
CGC   21.01 (+3.24%)
NVDA   196.61 (+0.30%)
BABA   169.58 (-2.27%)
TSLA   256.55 (+1.20%)
AMD   31.56 (-1.47%)
T   38.28 (+0.13%)
F   9.06 (+0.33%)
ACB   3.59 (-2.71%)
PRI   126.15 (+0.37%)
NFLX   267.61 (-3.75%)
GILD   66.03 (+1.26%)
DIS   132.97 (+2.08%)
S&P 500   3,003.80 (-0.10%)
DOW   26,865.18 (+0.14%)
QQQ   192.41 (-0.51%)
AAPL   240.85 (+0.14%)
MSFT   136.93 (-1.08%)
GOOGL   1,241.08 (-0.26%)
AMZN   1,766.27 (-1.09%)
CGC   21.01 (+3.24%)
NVDA   196.61 (+0.30%)
BABA   169.58 (-2.27%)
TSLA   256.55 (+1.20%)
AMD   31.56 (-1.47%)
T   38.28 (+0.13%)
F   9.06 (+0.33%)
ACB   3.59 (-2.71%)
PRI   126.15 (+0.37%)
NFLX   267.61 (-3.75%)
GILD   66.03 (+1.26%)
DIS   132.97 (+2.08%)
Log in

Translate Bio Stock Price, News & Analysis (NASDAQ:TBIO)

$8.86
+0.09 (+1.03 %)
(As of 10/22/2019 03:30 PM ET)
Today's Range
$8.75
Now: $8.86
$9.08
50-Day Range
$7.95
MA: $9.63
$10.72
52-Week Range
$4.81
Now: $8.86
$14.34
Volume4,149 shs
Average Volume313,759 shs
Market Capitalization$451.95 million
P/E RatioN/A
Dividend YieldN/A
Beta0.92
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TBIO
CUSIPN/A
CIKN/A
Phone617-945-7361

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.42 million
Book Value$2.78 per share

Profitability

Net Income$-97,390,000.00
Net Margins-2,696.98%

Miscellaneous

Employees81
Market Cap$451.95 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive TBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.


Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

How were Translate Bio's earnings last quarter?

Translate Bio Inc (NASDAQ:TBIO) released its quarterly earnings data on Wednesday, July, 31st. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.09. The company had revenue of $1.17 million for the quarter, compared to analysts' expectations of $1.73 million. Translate Bio had a negative net margin of 2,696.98% and a negative return on equity of 84.22%. View Translate Bio's Earnings History.

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Translate Bio.

What price target have analysts set for TBIO?

5 analysts have issued 1-year price objectives for Translate Bio's shares. Their predictions range from $17.00 to $25.00. On average, they anticipate Translate Bio's stock price to reach $21.60 in the next year. This suggests a possible upside of 143.8% from the stock's current price. View Analyst Price Targets for Translate Bio.

What is the consensus analysts' recommendation for Translate Bio?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Translate Bio.

What are Wall Street analysts saying about Translate Bio stock?

Here are some recent quotes from research analysts about Translate Bio stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to achievement of target price. Our price target of $21/share is based on an equally-weighted composite of: (a) $16.9/share, as a 35x multiple of taxed and diluted $4.33 discounted back to FY19 at 18% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $25.6/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/1/2019)
  • 2. According to Zacks Investment Research, "Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. " (7/16/2019)

Has Translate Bio been receiving favorable news coverage?

Media headlines about TBIO stock have trended extremely negative recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Translate Bio earned a coverage optimism score of -4.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Translate Bio.

Are investors shorting Translate Bio?

Translate Bio saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,540,000 shares, an increase of 5.8% from the August 30th total of 4,290,000 shares. Based on an average trading volume of 285,600 shares, the days-to-cover ratio is currently 15.9 days. Approximately 13.2% of the company's stock are short sold. View Translate Bio's Current Options Chain.

Who are some of Translate Bio's key competitors?

What other stocks do shareholders of Translate Bio own?

Who are Translate Bio's key executives?

Translate Bio's management team includes the folowing people:
  • Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 50)
  • Dr. Michael W. Heartlein, Chief Technology Officer (Age 60)
  • Mr. John R. Schroer C.F.A., CFA, CFO & Treasurer (Age 54)
  • Dr. Richard Wooster, Chief Scientific Officer (Age 59)
  • Mr. Paul D. Burgess J.D., Chief Legal Officer & Corp. Sec. (Age 45)

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Translate Bio?

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $8.86.

How big of a company is Translate Bio?

Translate Bio has a market capitalization of $451.95 million and generates $1.42 million in revenue each year. The company earns $-97,390,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Translate Bio employs 81 workers across the globe.View Additional Information About Translate Bio.

What is Translate Bio's official website?

The official website for Translate Bio is http://www.translate.bio/.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.


MarketBeat Community Rating for Translate Bio (NASDAQ TBIO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Translate Bio and other stocks. Vote "Outperform" if you believe TBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel